Business Wire

FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience

9.11.2022 11:00:00 EET | Business Wire | Press release

Share

Today, leading supply chain visibility company FourKites announced a partnership with Sony Network Communications Europe. The partnership will integrate data from Visilion — Sony’s real-time cargo and asset tracking solution — with FourKites’ real-time, end-to-end supply chain visibility platform. This collaboration will help enterprise customers solve their most complex use cases. Now, customers will be able to view FourKites’ real-time data for shipments in transit and in the yard, together with Visilion’s granular real-time data on cargo location and condition to provide best-in-class estimated times of arrival (ETAs) and enhanced end-customer experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience (Graphic: Business Wire)

Faced with ongoing global supply chain disruptions — including port congestion, port and rail strikes, global conflicts and more — businesses need more meaningful insights to mitigate preventable delays and damage, and to keep goods moving to their final destinations. Real-time visibility and actionable analytics regarding the location, temperature and status of shipments is critical, particularly for those in the Consumer Packaged Goods, Food & Beverage and Pharmaceutical industries, who ship products that require specific in-transit conditions to maintain quality.

“Businesses today require more high-quality, real-time supply chain data,” said Nimesh Patel, vice president of global alliances and partnerships at FourKites. “The Visilion solution from Sony provides an extra layer of granular data about the contents of containers and status of sensitive and/or temperature-controlled shipments. Our partnership will ensure that this data becomes more accessible than ever to businesses around the world.”

Visilion, Sony’s real-time cargo and asset tracking solution, offers industry-leading shock, tilt and temperature detection capabilities, among others, to ensure that goods are handled properly and maintained at the right temperature and humidity during transit, thereby mitigating losses. This functionality, combined with FourKites’ market-leading Dynamic ETA® across all modes, provides shippers with complete visibility into potential disruptions and product loss for goods in transit. In addition, FourKites’ international tracking capabilities, together with Visilion sensor data, provide an added dimension of granular visibility into ocean containers that often move through complicated, multi-stop journeys.

“FourKites’ shared commitment to industry-leading innovation, product quality and industry collaboration made them the obvious partner for us,” said Erik Lund, Head of Tracking Division, Sony Network Communications Europe. “We look forward to working together to provide our mutual customers with integrated supply chain data to fuel better decision-making and, ultimately, more efficient supply chain operations — in Europe and around the world.”

Over the last year, FourKites has experienced record growth in the European, Middle Eastern and African (EMEA) markets, achieving 97% growth in shipments YoY as of October 2022. The number of customers tracking loads with FourKites in EMEA grew 40% in the same time period, while the number of carriers tracking shipments grew by 50% in the same period.

About FourKites

Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 210 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
European PR Director for FourKites
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release

Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release

STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release

Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye